ZLB Behring L.L.C.

15 articles about ZLB Behring L.L.C.

• ZLB Behring Foundation Calls For Grant Applications

  11/16/2006

• ZLB Behring Names Robert D. Lefebvre, Ronan W. Gannon, Garrett E. Bergman, M.D., To Top U.S. Management Posts

  9/18/2006

• ZLB Behring Release: VIRTUE, Largest Clinical Trial Of Subcutaneous Immunoglobulin Therapy, Opens To Primary Immunodeficiency Patients Across The U.S.

  9/12/2006

• ZLB Behring Foundation Calls For Grant Applications

  6/22/2006

• ZLB Behring Foundation Awards Grants To Benefit Bleeding Disorders Community

  6/5/2006

• ZLB Behring Release: New International Study Group Seeks To Set Standards For Prevention, Treatment Of Bleeding In Patients With von Willebrand Disease (VWD)

  5/23/2006

• ZLB Behring Release: First International Census On Von Willebrand Disease (VWD): 77 Percent Of Patients With Severe Type 3 VWD Experience Significant Bleeding-Related Events

  5/22/2006

• State-Of-The-Art ZLB Behring Plant Licensed By The FDA

  4/18/2006

• ZLB Behring Release: Study Shows Individual Replacement Therapy With C1-Inhibitor Concentrate Reduces Life-Threatening Hereditary Angioedema Attacks Compared With Current Treatment Of Choice

  3/6/2006

• ZLB Behring Release: Study Finds Treatment With C1-Inhibitor Concentrate Relieves Abdominal Pain In Hereditary Angioedema Patients

  3/6/2006

• ZLB Behring Release: Phase III Clinical Study Shows Vivaglobin(R), A New Subcutaneous Immunoglobulin, Is Safe And Effective In Treating Patients With Primary Immunodeficiency

  3/6/2006

• ZLB Behring Announces Availability Of Humate-P(R) With Smaller Diluent

  2/15/2006

• ZLB Behring Announces FDA Approval Of Vivaglobin(R); The First Subcutaneous Immunoglobulin Replacement Therapy Approved In The U.S.

  1/10/2006

• ZLB Behring Release: Two-And-A-Half Million Women May Have A Bleeding Disorder ... Without Even Knowing It

  10/27/2005

• Aventis Behring Japan To Take Over Promotion Operations Of "Sanglopor" From UCB Japan

  1/15/2004